SandboxAQ has recently embarked on an innovative collaboration with pharmaceutical giant Sanofi, aiming to revolutionise the process of identifying biomarkers during clinical development. The partnership centres around the utilisation of SandboxAQ’s cutting-edge Quantitative AI models, designed for the task of filtering knowledge graphs in a manner that is both causal and efficient. This collaboration marks a notable advancement in the field of biotechnology by leveraging AI to streamline the extraction of clinical hypotheses from extensive literature.
The core of SandboxAQ’s contribution lies in its Large Quantitative Models (LQMs), which are trained on a variety of data streams, including proprietary data generated by SandboxAQ’s own algorithms. Unlike traditional models, which rely on public internet data and often face limitations in both scale and accuracy, these Quantitative AI models provide a more precise approach. By utilising these models, scientists are equipped to delve deeper into human biology, identifying new biomarkers and presenting evidence on the mechanism of action, efficacy, and safety of investigational drugs and targets.
Nadia Harhen, who oversees AI Simulation at SandboxAQ, expressed her enthusiasm about the collaboration with Sanofi. She noted that the application of LQMs in this context is particularly promising for biomarker identification, as it extends the utility of these models into later stages of clinical development. According to Harhen, such advancements have the potential to significantly enhance patient outcomes, extending benefits beyond the early stages of drug discovery to more advanced phases.
This partnership with Sanofi is not the first for SandboxAQ; the company has previously engaged in Quantitative AI collaborations with distinguished institutions including the University of California San Francisco (UCSF), Novonix, and Riboscience. Looking ahead, 2024 promises further developments, with organisations like Flagship Pioneering and SPARK NS on board to expand their innovation pipelines in collaboration with SandboxAQ.
Through these pioneering efforts, SandboxAQ continues to leave an indelible mark on the life sciences industry, demonstrating the powerful capabilities of AI in transforming traditional scientific research methods. This initiative stands as a testament to the ongoing evolution within the biotechnology sector, blending advanced technology with clinical research to pave new paths in the identification and development of biomarkers.
Source: Noah Wire Services